Abstract Introduction Identifying central sleep apnea (CSA) during home sleep apnea testing is important to guide appropriate treatment for sleep-disordered breathing (SDB) and underlying cardiovascular conditions, including heart failure and atrial fibrillation. SANSA (Huxley Medical, Inc.) is a multi-diagnostic chest-worn monitor capable of detecting SDB, cardiac arrhythmias, and heart function. Using polysomnography (PSG) as a reference, we developed a machine learning (ML) method to classify respiratory events from this monitor as central or obstructive. Methods Data was analyzed from ninety-five subjects with suspected SDB who wore the chest monitor simultaneously with PSG overnight. To address known scoring heterogeneity of CSA, PSG records were scored for central apneas by two core laboratories (Core 1 and Core 2). Core 1 annotations from twenty-eight records were first used to train a random forest classifier to differentiate obstructive (N=680) and central events (N=388). The model used oximetry, respiratory effort, and snoring to classify events based on effort, duration, and other features. A five-fold cross validation was used to evaluate event-level performance. The model was then used to estimate subject-level CAI for all subjects and compared with Core 2 scores. Results Algorithm event-level sensitivity and specificity to detect central events was 72.7% and 81.0%. Subject-level CAI for all records between the chest monitor and Core 2 had a correlation coefficient of 0.90 and root mean squared error (RMSE) of 4.6 events/hour, versus 0.82 and 4.7 events/hour comparing Core 1 and Core 2. Sensitivity and specificity to detect CAI≥10 events/hour was 80.0% (4/5) and 98.9% (89/90), compared to 100% (3/3) and 98.9% (91/92) for CAI≥15. Conclusion An ML algorithm to differentiate obstructive and central events collected from the chest-worn monitor demonstrated favorable event-level performance and comparable CAI agreement to that between two PSG core laboratories. Home-based CSA detection alongside cardiac monitoring could identify high risk patients for expedited therapy, cardiology referral, or follow-up PSG. These results motivate further validation in a larger cohort as well as investigation of outcomes related to time to evaluation and management. Support (if any) National Science Foundation; Georgia Research Alliance; Huxley Medical, Inc.
EEG burst dynamics as an indicator of a progressive hypoxic state
This study reveals how EEG burst activity changes with progressive hypoxia, offering insights into its neural correlates. Increased burst features in specific frequency bands correlate strongly with physiological, such as decreasing peripheral oxygen, task performance, such as declining accuracy, and symptom measures, such as increasing report rate. Our findings characterize a neural signature with potential use for real-time EEG monitoring to enhance hypoxia detection in aviation, potentially improving flight safety.
Trends in Patch Test Results With the Mayo Clinic Extended Standard Series: A 14-Year Retrospective Review (2010–2023)
Abstract: Background: Extended patch testing beyond the standard series is commonly performed in patients with allergic contact dermatitis. This broader testing allows for more precise and complete allergen identification, ultimately leading to improved clinical outcomes. Objective: To report the Mayo Clinic Contact Dermatitis Group (MCCDG) patch testing results using a custom extended series from 2010 to 2023. Methods: A retrospective review of patch testing results using the MCCDG extended standard series at the Mayo Clinic was conducted. Data from 2010 to 2023 were analyzed. Results: Patch testing with the extended standard series was performed in 3,767 unique patients, with a total of 3834 extended standard patch tests administered (81.8% in women, 18.2% in men). The top 5 allergens eliciting positive reactions were gold (I) sodium thiosulfate (10.4%), benzisothiazolinone (10.4%), carmine (9.4%), thimerosal (9.3%), and hydroperoxides of linalool (8.8%). Conclusions: The extended standard series expands the diagnostic scope for patients in whom the standard series incompletely identifies relevant allergens. Preservatives and fragrances remain among the most common sensitizers, emphasizing the need for ongoing allergen surveillance, periodic review, and updates to patch test series to enhance diagnostic accuracy and patient care.
The Influence of Depressive and Manic Symptoms on Suicidal Ideation in Mixed Mood States
Abstract Background: While bipolar disorder is strongly linked to an increased risk of suicide, recent evidence has challenged the assumption that mixed symptoms play a distinct role in suicidal ideation beyond depressive severity. This study examines how depressive, hypo/manic, and mixed features influence suicidal ideation in individuals with bipolar disorder. Data from 903 participants in the Stanley Foundation Bipolar Network (1995–2002) were analyzed to assess associations between mood states, classified by the Inventory of Depressive Symptomatology–Clinician-Rated (IDS-C) and the Young Mania Rating Scale (YMRS), and suicidal ideation, measured using IDS-C item 18, using generalized estimating equations. Results: Depressive symptoms were strongly associated with suicidal ideation (OR = 21.98, 95% CI: 15.31–31.54). Moderate hypo/manic symptoms also conferred risk (OR = 3.11, 95% CI: 1.51–6.49), and milder hypo/mania showed a weaker but significant association (OR = 1.74, 95% CI: 1.05–2.89). The highest suicidal ideation was observed in individuals with hypo/mania featuring mixed symptoms (OR = 29.43), exceeding that of depression or depression with mixed features (OR = 21.98). However, findings diverged based on modeling approach: in continuous predictor models, SI was driven solely by depressive symptom severity, with no significant association observed for hypo/mania or its interaction with depression. In contrast, when mood states were categorized using clinically meaningful thresholds, hypo/mania with mixed features emerged as a distinct contributor to suicidal ideation risk. Conclusion: These findings underscore the need for integrating both dimensional and categorical approaches to mood state classification in research on suicidality in bipolar disorder.
Data Interoperability and Harmonization in Cardiovascular Genomic and Precision Medicine
Despite advances in cardiovascular care and improved outcomes, fragmented healthcare systems, nonequitable access to health care, and nonuniform and unbiased collection and access to healthcare data have exacerbated disparities in healthcare provision and further delayed the technological-enabled implementation of precision medicine. Precision medicine relies on a foundation of accurate and valid omics and phenomics that can be harnessed at scale from electronic health records. Big data approaches in noncardiovascular healthcare domains have helped improve efficiency and expedite the development of novel therapeutics; therefore, applying such an approach to cardiovascular precision medicine is an opportunity to further advance the field. Several endeavors, including the American Heart Association Precision Medicine platform and public-private partnerships (such as BigData@Heart in Europe), as well as cloud-based platforms, such as Terra used for the National Institutes of Health All of Us, are attempting to temporally and ontologically harmonize data. This state-of-the-art review summarizes best practices used in cardiovascular genomic and precision medicine and provides recommendations for systems’ requirements that could enhance and accelerate the integration of these platforms.
Cerebrospinal fluid diversion procedure utilization and physician reimbursement in adult hydrocephalus patients
Background As the population continues to age, the number of adults receiving care for hydrocephalus is expected to increase. Here, we assess trends in the utilization and physician reimbursement for ventriculoperitoneal shunts (VPS), lumboperitoneal shunting (LPS), and endoscopic third ventriculostomy (ETV) for adult hydrocephalus. Methods The Medicare Part B National Summary Data files from 2000 to 2021 were collected, and information was extracted on procedures performed per year, total charges billed, and actual payments. Linear mixed-model regression analyses were conducted to assess the significance of changes in procedural volume and physician reimbursement over time while adjusting for inflation. Results Over the period studied, there was a 26% increase in VPS placement (P = 0.11), 11.34% increase in ETV utilization (P < 0.01), and 43.1% decrease in LPS utilization (P < 0.01). This corresponded to annualized changes of + 4.29% for ETV procedures, −8.78% for LPS, and + 45.8% for VPS. There was a statistically significant difference in the change of rate of number of procedures annually between LPS and VPS (P = 0.04). In both inflation-unadjusted and inflation-adjusted analyses, all procedures experienced an annual decline in reimbursement with inflation-adjusted changes of −11.54%/year for ETV, −4.13% for LPS, and −13.12% for VPS. There was a statistically significant difference in the change of rate of reimbursement between LPS procedures and both ETV (P < 0.01) and VPS (P < 0.01). Conclusion Medicare reimbursement data shows that a commensurate decline in physician reimbursement has accompanied the ongoing rise in adult hydrocephalus procedures.
Abstract 574: Detection of tumor cell surface calreticulin after doxorubicin treatment using a novel radiolabeled nanobody
Abstract Background: Targeted agents, such as nanobodies, can be covalently linked to radionuclide chelators for theranostics. Nanobodies are single-domain immunoglobulin variable regions with a short blood half-lives and high specificity. Calreticulin (CALR) is endoplasmic reticular (ER) protein that translocates to the cell surface upon induction with certain agents, namely doxorubicin. We hypothesized surface CALR on tumors could be targeted using a novel nanobody after induction with doxorubicin. Methods: Studies were conducted using in vitro and in vivo models of pancreatic ductal adenocarcinoma (PDAC). Surface CALR expression was determined by western blot on fractionated lysates, flow cytometry, or immunofluorescence (IF). Doxorubicin was administered by intraperitoneal injection to mouse models of PDAC. The anti-CALR nanobody was developed via the panning of a synthetic nanobody phage display library. The top CALR-binding nanobody was confirmed by ELISA, immunohistochemistry (IHC), and flow cytometry. For in vivo studies, the nanobody was conjugated with the chelator NOTA and radiolabeled with 64Cu. PET images were acquired 1-hour after injection. Significance was determined using an independent t-test and p values < 0.05 were considered statistically significant. Results: PDAC cells treated with doxorubicin showed peak surface CALR expression between 24 and 48 hours. Flow cytometry revealed that 61.7% of live PDAC cultured cells treated for 24 hours expressed surface CALR, compared to 2.2% in controls (p < 0.001). In a subcutaneous syngeneic PDAC mouse model, two doses of doxorubicin 48 hours apart significantly increased surface CALR, with 30.4% of live-cells expressing CALR in treated tumors versus 1.5% in controls (p < 0.001). Similarly, doxorubicin-treated tumors from a PDAC patient derived xenograft (PDX) model had a 6.7-fold increase in live-cells expressing surface CALR compared to controls (p < 0.01). IF confirmed a 1.4-fold increase in CALR expression in doxorubicin-treated tumors from the subcutaneous PDAC mouse model (p < 0.01) and a 1.7-fold increase in the PDAC PDX model (p < 0.01). Our anti-CALR nanobody has an apparent 37 nM affinity for recombinant CALR and successfully detected surface CALR by IHC and flow cytometry. In vivo PET imaging showed significant increased uptake of the 64Cu-NOTA-nanobody in tumors from doxorubicin-treated mice over controls, with no significant changes in heart, kidney, or liver accumulation by PET quantification and flow cytometry (p < 0.05). Conclusions: Systemic doxorubicin treatment induces CALR surface translocation in tumors that can be successfully targeted with a radiolabeled nanobody for PET imaging. Targeting chemotherapy-induced surface CALR using our radiolabeled nanobody could provide a theragnostic strategy for the detection and treatment of PDAC. Citation Format: Rachael Guenter, Yuvasri Golivi, Lucinda Hall, Amro Abdelrahman, Chloe La Prairie, Caleb Miller, Tejeshwar C. Rao, Danielle M. Carlson, Mark J. Truty, Benjamin Larimer, J. Bart Rose. Detection of tumor cell surface calreticulin after doxorubicin treatment using a novel radiolabeled nanobody [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 574.
Abstract 6526: Phylogenetic and metagenomic analysis of the human pancreatic cancer microbiome
Pancreatic cancer ranks third in cancer related deaths in the USA, however, no reliable theragnostic biomarker exists for the disease. The community of bacteria within the body can become dysbiotic and promote cancer through inflammation and other means. The objectives of this study were to determine the identity and abundance of bacterial species in the gut of mice before and after development of pancreatic cancer. As there can be significant variation in the genomes of different strains of bacterial species, a metagenome analysis was also performed. We hypothesized that there would be significant variation in species and genes of the gastrointestinal tract of mice before and after xenografting with pancreatic cancer. A decrease in ecological diversity was also predicted. Fifteen female SCID mice were divided into three cages. To develop the SubQ pancreatic cancer model, 5 X 106 Panc1 cells were injected at the flank. Fecal materials were collected prior to tumor cell implantation and after tumor development. DNA was extracted from the fecal material. For phylogenetic analysis the seven variable regions of the 16S rRNA gene were amplified and sequenced. Metagenomic analysis was performed as well. Average tumor size in mice after 40 days was ∼ 32 mm3. Microbial diversity was decreased in two out of the three groups of mice. Principle component analysis showed major differences between all samples. There were at least 15 OTUs in each set of samples specific to pretumor mice and 15 OTUs specific to tumor bearing mice. One genus of bacteria, Alistipes, was specific to each set of tumor bearing mice. Taxa at significantly increased abundances in tumor bearing mice included Prevotellaceae and Porpyromonadaceae. Moreover, there were several gene functions that were enriched in tumor bearing mice. This study produced data that demonstrates that there is a link between health status and the gut microbiome. However, this is not a new idea. This study could serve as foundation to establish a gut microbiota profile of pancreatic cancer. Precision medicine is becoming more common due to the decreasing costs of DNA sequencing. The findings of our investigation strengthens the hypothesis that there is an interaction between gut microbiome and pancreatic cancer development and bacteria or bacterial genes could serve as theragnostic biomarker for pancreatic cancer. Acknowledgement: This research was supported by NIH Grant# T34-GM100831, NSF-NOYCE Graduate student training award, a US Department of Education Graduate student training award to Elizabeth City State University Campus of The University of North Carolina and a University of North Carolina Collaboratory Grant award to Dr. H. Banerjee and Dr. Colby Hunter. Citation Format: Gabrielle Morgan, Colby Hunter, Michael Hall, Narendra Banerjee, Erik Armstrong, Kanisha McNeil, Karington Perry, Santanu Bhattacharya, Hirendra N. Banerjee, Krishna K. Rachamala, Shamit Dutta, Naga M. Nakka. Phylogenetic and metagenomic analysis of the human pancreatic cancer microbiome [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 6526.
Abstract MP24: Socioeconomic Disparities in Cardiac Rehabilitation Perceptions and Delivery Mode Preferences: A Nationally Representative Survey Among Diverse Cardiac Patients.
Background: Cardiac rehabilitation (CR) is essential to secondary cardiovascular disease prevention and management of cardiac patients. Despite its proven benefits, CR remains underutilized with enrollment and completion rates ranging from 10-30% in the US. Yet, there is a scarcity of nationally representative data among diverse populations on socioeconomic differences in barriers and beliefs of CR participation and delivery mode preferences. Hypothesis: The perceptions (barriers, beliefs), CR delivery mode preferences, and CR utilization (prior enrollment) varies by socioeconomic status (SES) among CR-eligible individuals. Methods: We conducted an anonymous national electronic survey from March 2023 to January 2024 of individuals self-reporting a prior CR-eligible diagnosis. The 22-item CR Barriers Scale assessed perceived barriers to CR enrollment and participation using a 5-point Likert scale (strongly disagree to strongly agree). A 13-item, validated questionnaire assessed 4 subscales pertaining to patients’ beliefs about CR, each rated on a 5-point Likert scale (strongly disagree to strongly agree): perceived necessity, concerns about exercise, practical barriers and perceived suitability. CR delivery mode preferences were ascertained (eg, virtual, at-home, etc.). Mean barriers and belief scores as well as delivery mode preferences were stratified by SES. Low SES was defined as ≤ high school education, Medicaid insurance, or uninsured. High SES was defined as > high school education and non-Medicaid health insurance. Responses were analyzed using descriptive statistics with R software. Results: A total of 466 participants completed the survey (38.1% women, 30.6% minoritized racial/ethnic group, 29.6% low SES, 95% response rate) ( Table 1 ). The majority indicated prior enrollment in CR (81.5%) with no difference by SES. CR barrier scores did not differ significantly by SES (p=0.331) ( Table 2 ). Beliefs about CR perceived necessity and perceived suitability differed by SES (p<0.001 and p=0.025), but beliefs regarding concerns about exercise and practical barriers did not. The low SES group reported a higher preference for completely at-home CR compared to the high SES group (33.6% vs 7.4%, p<0.001). Conclusion: Our findings suggest that CR beliefs varied by SES while utilization did not. For CR-eligible patients experiencing socioeconomic disadvantage, at-home CR may be a preferred alternative to center-based CR to increase CR participation and adherence.
Biochemical Assay to Aid in the Diagnosis of SORD Deficiency (P7-2.012)